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In recent years, engineering the total morphology of pharmaceutical materials particles to
desirable shape, size and surface area has long been actively increased because it has
many advantages especially for improving physicochemical properties of Active Pharma-
ceutical Ingredients (APIs). This article therefore considers the potential utility of crystal
engineering as a tool for controlling and designing properties of pharmaceutical solid
particles in purpose to developing efficacious performance of solid dosage form, funda-
mentals of crystallization process, applications. In addition, understanding the relation-
ship between molecular recognition, thermodynamic, and kinetics which controls the
crystallization process so that it benefits in designing successful experiments to have
desirable crystal habit for materials.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Drug molecules with limited micromeritic properties &
aqueous solubility (about 90% of new API's having low solu-
bility in water) [1] are becoming increasingly prevalent in the
research and development of new drugs [2]. Nowadays,
increasing energy prices and the inefficient manufacturing
have made pharmaceutical companies face cost pressures.
Therefore, the primary aim of pharmaceutical material engi-
neering is to improve designed particles of solid pharmaceu-
tical dosage formswhich results in improving the efficiency of
the manufacturing processes and giving a high degree ofaceutical Technology, Fa
-Zhry El-Yafi), hindalzen@
g Pharmaceutical Univer
University. Production an
ns.org/licenses/by-nc-ndfunctionality to the drug or excipient particles (especially of
pharmaceutical materials for direct compression) [3] in
pharmaceutical products. Materials in the solid state
depending on the internal packing of their molecules can be
found in either crystalline, polymorphism or amorphous (or a
combination of both). It has been shown that they can be
packed in a defined order (crystalline), have no long-range
three dimensional (3-D) order (amorphous) have different
repeating packing arrangements (polymorphic crystals) or
have solvent included (solvates and hydrates). Each of these
changes in internal packing of a solid will give rise to changes
in bulk properties such as physiochemical, mechanical, etc.
[4]. For the crystal form, it is possible to change the externalculty of Pharmacy, Damascus University, Damascus, Syria.
yahoo.com (H. El-Zein).
sity.
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the consequence of the rate at which different faces grow.
Changes in internal packing usually (but not always) give an
easily distinguishable change in the crystal habit. With any
crystalline material, the largest face is always the slowest
growing and some crystal facesmay havemore exposed polar
groups and othersmay be relatively non-polar that are depend
on the packing geometry of the molecules into the lattice. In
other words, the growth on different faces will depend on the
relative affinities of the solute for the solvent and the growing
faces of the crystal. It is technically possible to engineer
changes in crystal habit by deliberately manipulating the rate
of growth of different faces of the crystal [5]. Crystallization,
particularly crystallization from solutions, is the vitally
important operation in the production of pharmaceutical solid
particles because most of drug particles (<90%) are delivered
in crystalline form [1] and it benefits in determining the purity
(chemical and structure) and the physical properties of a
material which are summarized in Table 1.
However, changes in crystallization conditions can signif-
icantly alter their previous properties followed by thermody-
namic and mechanical properties [6].
Powder technology is the base of dosage form design with
effective drug delivery. Any particles of pharmaceutical solid
materials may be produced by two ways:
 Constructive methods: include crystallization, spray-drying,
lyophilization, and supercritical fluid techniques.
 Destructive methods: include milling and grinding.
In general, crystallization is the most common method of
particle production [7].T
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of pharmaceutical materials
2.1. The role of thermodynamic in the crystallization
process
The phase change with stability associated with crystalliza-
tion processes can be explained by rules of physical chemistry
and thermodynamic principles. When a substances is trans-
formed from one phase to another, the change in the molar
Gibbs free energy (DG^) of the transformation, at constant
pressure and temperature, is given by:
where m1 and m2 are the chemical potentials of phase 1 and
phase 2, respectively. When DG^ < 0, the transition from phase
1 to 2 is spontaneous under specific conditions (in case of
supersaturated solution). Alternatively, when DG^ > 0, this
phase transformation is not thermodynamically possible (in
case of unsaturated solution); whereas, DG^ ¼ 0 defines a
condition of thermodynamic equilibrium in the system, in
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 8 3e2 9 1 285this situation, the free energy of two phases is the same [8] (in
case of saturated solution) and the process can divided as
follows [9]:A supersaturated solution can be achieved in general by
under cooling if dCeq/dT > 0 or by evaporation the solution if
dCeq/dT < 0. If T0 is the solute's saturation temperature for a
given solvent system, then at some temperature T, DG^ can be
demonstrated in terms of heat effects as:
DbG ¼  Z
T
T0
DS
_
dT ¼ DH_
ðT T0Þ
T0

where DS^ is the molar entropy and DH^ is the enthalpy change
for the phase transformation. Themolar Gibbs free energy can
also be expressed in terms of activity as:
DbG ¼ RT ln a
a0

¼ RT lnðSÞ
where R is the universal gas constant, T is the absolute tem-
perature, ɑ is the activity of the solute and ɑ0 is the activity of
the pure solute in equilibrium with a macroscopic crystal, S is
the saturation ratio which is given by:
S ¼ C
Ceq
where C is the solute concentration and Ceq is the equilibrium
solubility of the solute at the temperature and pressure of the
system; from this, the supersaturation ratio can be defined as:

C Ceq

Ceq ¼ S 1
These thermodynamic considerations describe a driving
force for crystallization [10].
2.2. Crystallization process and factors affecting in
crystal habit
2.2.1. The crystallization mechanism
Because of instability of many amorphous materials, most
drugs are formulated in the crystalline state [4]. Crystals are
produced by inducing a change from the liquid to the solid
state. Crystallization from solution can be considered to be the
result of relative rate of the three successive processes:
 Supersaturation of the solution.
 Formation of crystal nuclei.
 Crystal growth round the nuclei [10].
A Supersaturated Solution Step:Supersaturated solution, a chemical potential and essen-
tial requirement for crystallization process, is the driving force
for nucleation and crystal growth. It can be expressed as the
concentration divided by the solubility (C/S). Supersaturation
can be defined as any solution that contains more dissolved
solid (solute) than that can be found in saturation conditions
[11]. Supersaturated solutions are not thermodynamically
stable; in these circumstances the system will adjust in order
to move back to the true solubility and to do this the excess
solutewill precipitate [5]. This supersaturated solutionmay be
achieved by several methods including [8] and [10]:
1 Methods that produce supersaturation by increasing the solute
concentration: include:
a. Removing the solvent liquid by evaporation (this is the
way sea salt is prepared): for systems (isothermal solu-
tion) in which the solubility is not a strong function of
temperature.
b. Dissolution of a metastable solid phase like amorphous,
anhydrous, more soluble, and salt which trans-
formation to crystalline, hydrate, less soluble poly-
morph, and free acid or base, respectively).
2 Methods that produce supersaturation by decreasing the solute
solubility: include:
a. Cooling the solution, as most materials become less
soluble when the temperature is decreased: for systems
in which solubility increases with temperature.
b. Adding another solvent which will mix with the solu-
tion, but in which the solute has a low solubility. This
second solvent is often called an anti-solvent (i.e.
water).
c. Adding precipitants or by a chemical reaction that
change the nature of the solute.
d. pH changing.
The terms labile (unstable) and metastable zones can
classify supersaturated solutions in which spontaneous
nucleation would or would not occurs, respectively. These
zones are presented in a solubility diagram as shown in Fig. 1.
Above the equilibrium line (solid line): the solution are at
supersaturation. In the labile zone, nucleation can occur
spontaneously which is called primary nucleation. In meta-
stable zone, no nucleation occurs which means that super-
saturation itself is insufficient to cause crystal formation. The
crystal embryos must form by collision of molecules of solute
in the solution or sometimes by the addition of breakage of the
seed crystals or dust particles or even particles from container
walls.
Deliberate seeding is often carried out in industrial pro-
cesses, seeding crystals are not necessary to be of the sub-
stances concerned butmay be isomorphous substances (i.e. of
the same morphology) [11] and [12].
B Nucleation step:
Nucleation is the formation of a small mass on which a
crystal can grow [5]. There are three types of nucleation that
can occur in supersaturated solutions. These types are pre-
sented in nucleation situations diagram as shown in Fig. 2.
Fig. 1 e The solubility diagram representing themetastable
zone [11].
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 8 3e2 9 12861 Primary homogeneous nucleation:
This is spontaneous nucleation where the formation of the
solid phase particle is not brought by the presence of any solid
phase. It requires very high supersaturation conditions such
as in the labile zone [8], [11], and [13].
2 Primary heterogeneous nucleation:
Is themost primary nucleationwhere the formation of new
solid phase particle is catalysed by the presence of a foreign
solid phase which has lower surface energy than that of a new
solute particle. Therefore, it requires lower supersaturation
than homogeneous nucleation [10] and [13]. However, homo-
geneous and heterogeneous can be presented in same the
nucleation process as follow:
Shomo >Shetero
where S is a saturation ratio of solution [10].
3 Secondary heterogeneous nucleation:
It is the most common nucleation event in industrial
crystallization and is the mechanism by which formation of
the solid phase is initiated when solid phase of solute particle
can be present or added to solution. Therefore, this type of
nucleation can be found even in the metastable zone where
the crystals seemingly only grow [10], [11], and [13].Fig. 2 e The nucleation situations from solution [7].In recent years, the theory of two step nucleation model
has attracted attention, supported by various studies and
observed especially in proteins and colloidal systems [14e18].
In this theory, nucleation proceeds through a dense liquid
(amorphous) step before ordering into the growth structure to
form a three-dimensional lattice structure [19].
The two steps progression from liquid to crystalline nuclei
observed in colloid experiments can be seen in Fig. 3. As soon
as stable nuclei are formed, they begin to grow into visible
crystals [18]. The macromolecules nucleation such as colloi-
dals, proteins and polymers can be observed by using tech-
niques that are summarized in Table 2. Such as optical
microscopy, small-angle neutron scattering and atomic force
microscopy (AFM) [20e23]. which the effective technique to
qualitatively study-surface morphology and crystal growth
processes [24]. In order that there is more chances to control
the rate of nucleation step which affects in morphology of
crystal particles. As far small molecules, direct measurement
and observation of nucleation of nuclei is impossible so
crystal particles can be observed only after growth to larger
size through growth step [23].
C Crystal growth step:
Crystal growth is the addition of more solute molecules to
the nucleation site or crystal lattice to evolution macroscopic
crystal form of defined size and shape [5]. In other words, Par-
ticle size distribution andmorphologies producedare a result of
the relative rates of reaction of nucleation, crystal growth [10].
Crystal growth is considered to be a reverse dissolution
process and the diffusion theories of Noyes andWhitney, and
of Nernst, consider that matter is deposited continuously on a
crystal face at a rate proportional to the difference of con-
centration between the surface and the bulk solution. So an
Equation (1.1) for crystallization can be proposed in the form:
dm
dt
¼ AKmðCss  CsÞ (1.1)
where m is the mass of solid deposited in time t, A is the
surface area of the crystal, Cs is the solute concentration at
saturation and Css is the solute concentration at supersatu-
ration. As km ¼ D/d (D being the diffusion coefficient of the
solute and d the diffusion layer thickness), the degree of
agitation of the system,which affects d, also influences crystal
growth. Crystals generally dissolve faster than they grow and
depend on their initial size [12] and [25], so growth is not
simply the reverse of dissolution. It has been suggested that
there are two steps involved ingrowth in addition to those
mentioned earlier [12].
However, crystal growth process consists of several stages
through the growth unit. The growth unit in turn describes the
critical elements of how a specific molecular species has
assembled in a crystalline state in three dimensions, so that
crystal growth depend on strength of the interactions (espe-
cially, if there is hydrogen bonding between functional group,
Fig. 4) between molecules itself and also between growth
layers in network structure which would change in overall
morphology of the crystal [2]. These stages include [7], [23],
[26], and [27]:
Fig. 3 e Two-step nucleation of colloidal particles. Image (a) shows the initial diluted liquid phase, (b) shows the amorphous
dense droplets are first created from mother phase, followed by (c) the crystalline nuclei are created from the amorphous
phase [18].
Table 2 e Physical approaches for studying macromolecular crystallization [24].
Method Use
Static/quasi-elastic light scattering Nucleation, phase transitions
Michelson interferometry Growth kinetics
MacheZehnder interferometry Concentration gradients in solutions
Atomic force microscopy Growth mechanisms, kinetics, defect structure, defect density
Fluorescence polarization Nucleation
Low angle neutron scattering Nucleation
Osmometry Nucleation
Light microscopy Characterization of crystal
Time lapse video microscopy Growth kinetics
X-ray diffraction Characterization of crystal
Numerical simulation/modeling Nucleation, growth kinetics, phase transitions.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 8 3e2 9 1 2871) Transport of a growth unit (a single molecules, atom, ion,
or cluster) from or through the bulk solution to an
impingement site on the crystal face by convention and
diffusion, which is not necessarily the final growth site (i.e.
site of incorporation into the crystal).
2) Adsorption of the growth unit at the impingement site.
3) Diffusion of the growth units from the impingement site to
a growth site.
4) Incorporation into the crystal lattice.
5) The latent heat of crystallization is released and trans-
ported to the crystal and solution.
Desolvation of the growth unit may occur anywhere in
steps 2e4, or the solvent may be adsorbed with the growthFig. 4 e Representative superior hydrogunit. In general, three types of crystal surfaces (and thus
growth sites created by these surfaces) can be observed
when impingement site captured the arriving growth units:
Kink, Step, and Flat faces, which provide three, two, and one
surface bond(s), respectively Fig. 5 [28]. As well, any of these
steps can be the rate-limiting step in the crystal growth
process and which step is rate-limiting will depend on the
solvent properties like viscosity [8]. When the diffusion of
molecules from the bulk solution to the impingement site is
the rate-limiting step, crystal growth is volume-diffusion
controlled whereas if the incorporation of a growth unit into
the lattice is the slowest process then crystal growth is
surface-integration controlled [8], [11], and [29]. At last, the final
shape of crystal is defined by the slowest growing flat faces.en bonding in supramolecular [2].
Fig. 5 e A three-dimensional crystal surface showing three
type of growth sites [28].
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 8 3e2 9 1288Crystal growth studies are therefore concerned with the
mechanisms by which these faces grow [5].
2.2.2. Factors affected of crystal habit
If the crystallization conditions are changed in any way.
Therefore, it is possible that the molecules may start to form
crystals with a different packing pattern and different tuning
crystal facets from that which occurred when the original
conditionswere used. The change in some conditions could be
change in the rate and mechanism of crystallization process
in crystal growth step, specifically. Hence, the art of crystal
facet engineering is determined by numerous factors that
regarded in thermodynamic, kinetics, and molecular recognition.
These factors are summarized in Fig. 6 [30].
In general, a knowledge of how crystal grow from the
crystal nuclei and the effects of the various factors whichmay
influence crystal growth is not studied from pharmaceuticalFig. 6 e Schematic diagram showing the interplay between therm
that governs crystallization [30].viewpoint in as much as chemical or physical viewpoints. So
crystal growth for any pharmaceutical ingredients may be in
general affected by two factors [31], [32], and [33]:
 Rate-controlling process for crystal growth:
The rate at which a crystal grows can be controlled by any
of three factors: diffusion from the solution to the crystal
nuclei as well as surface integration mechanisms, flow of
latent heat away from the growing crystal surface (under
cooling stage), and reactions at the crystalesolution interface.
 The stability of planar interfaces relative to cellular
interfaces.
Moreover, new drugs are screened to see how many poly-
morphs exist, and then to identify which one is the most
stable. The screening process requires a lot of work in crys-
tallizing from different solvent system, with variations in
method and conditions, in order to try to cause different
polymorphs to form. The products are then checked with
spectroscopy (e.g. Raman) and X-ray diffraction to see if they
have different internal packing [5].
2.2.3. Effect of crystal habit on the performance of a
pharmaceutical powders
Changing in crystal habit to any solid state in crystal and
powders of both drugs and pharmaceutical excipients are
interested because it can be change in physicochemical
properties for it like surface energy (which can be determined
by gravimetric, calorimetric and chromatographic), density,
flowability, compressibility, melting point, solubility, physical &
chemical stability and biopharmaceutical behaviour (dissolution,odynamic, kinetic, and molecular recognition phenomena
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 8 3e2 9 1 289bioavailability) because these depend on the size and number
of crystal faces in crystal habit which affect both the pro-
duction of dosage forms and the performance of the finished
product [5]. As mentioned above, many properties can be
change when a material is in a different polymorphic form in
specific micromeritic properties, such as flowability, and a
good reproducible compressibility. At all events, the flow-
ability of needle-shaped or plated-shaped crystals is very
poor and these crystals are difficult to handle [34]. For
example, Ibuprofen is usually crystallized from hexane as
elongated needle-like crystals, which have been found to
have poor flow properties that due to surface atomic
arrangement and surface affinity for the solvent to each
orientation is different which can affect in final shape of the
crystal [23]; crystallization from methanol produces equi-
dimensional crystals with better flow properties and
compaction characteristics, making them more suitable for
tableting, plate-like crystals of tolbutamide cause powder
bridging in the hopper of the tablet machine and also capping
problems during tableting [12]; crystallization by a
temperature-cooling method [35] and by a solvent-change
method [36] modified the size, shape of particles so it had
improved the compressibility and had a higher dissolution
rate of tolbutamide, respectively. Another consideration,
crystallization process in aqueous solution at different pH
values (1,7, and 11) affected the morphology and size of
carbamazepine crystals, the shape of this crystals was
changed from flaky or thin plate-like to needle shape which
improve better compaction and higher dissolution rate than
the original carbamazepine powder [37]. Paracetamol is a
high-dose drug with poor compression properties, which can
make it difficult to form into tablets, Consequently, re-
searchers have tried to use different polymorphic forms of
paracetamol to find one that is more compressible, for
Nichols and Frampton are found this drug was exist in two
polymorphic forms according to crystallizationmethod used,
a common crystal form is a form I (monoclinic) was describedFig. 7 e Comparison of mean blood serum levels after the
administration of chloramphenicol palmitate suspensions
using varying ratios of the stable (a) and the metastable (b)
polymorphos. M, 100% a polymorph; N, 25:75 b:a; O, 50:50
b:a; P, 75:25 b:a; L, 100% b polymorph [41].as plate-shape (Thermodynamically stable at room temper-
ature, the commercially used form, and not suitable for
direct compression which leads to unstable tablets with high
capping tendency) and form II (orthorhombic) was a pris-
matic crystal show better compression behaviour (have a
plastic deformation upon compaction so it suggested to use
in direct compression) [38], and [39]. The disadvantage of the
orthorhombic form is the possible transition to form I [40].
In general there will be a correlation between the melting
point of the different polymorphs and the rate of dissolution,
because the onewith the lowestmelting point will most easily
give up molecules to dissolve, whereas the most stable form
(highest melting point) will not give up molecules to the sol-
vent [5].
High melting point ¼ strong lattice ¼ hard to remove a
molecule ¼ low dissolution rate (and vice versa)
A classical example of the importance of polymorphism on
bioavailability is that of chloramphenicol palmitate suspen-
sions in the late 1960s. In Fig. 7 the blood serum level is plotted
as a function of time after dosing. It can be seen that the stable
a-polymorph (have low free energy) produces low serum
levels, whereas the metastable b-polymorph (have high free
energy so have greater solubility, absorption, and bio-
avilability) yields much higher serum levels when the same
dose is administered [2], [5], and [41].
Moreover, Norvir™, a semisolid capsules product which
produced by Abbott company was failed in dissolution test
after being in market that due to appearance of a new more
stable crystalline polymorph of ritonavir (Form II) which held
a lower thermodynamic solubility than the marketed (Form I)
[42]. The effect of a solvent or solvent mixture on the forma-
tion of erythromycin crystals was studied and the results
illustrated that using solvent mixture of acetone and ethanol
(3:1, v/v) induced the good shape and high purity crystals by
comparison with other solvents such as isopropyl, 1 propanol
[43]. In addition, some anti-inflammatory drugs for pulmo-
nary delivery such as bedomethasone, dipropionate, beta-
methasone, prednisolone were micronized by controlled
crystallization process without any milling process by using
solvent changemethodwhich improves powder properties for
inhalation [44],moreover, zinc-free insulin crystals can be
prepared in the inhalation size range of 0.2e5 mmby using the
solvent change (antisolvent precipitation) method [45]. On the
other hand, synthesis, crystallization, separation and
agglomeration can be incorporation in one step which defined
as spherical crystallization; one must be mentioned, this
technique can improve mechanical properties like
compressibility, packability and flowability for API's powders
such as naproxen, aminophylline, and salicylic acid crystals
[46e48].3. Growth rate dispersion & factors affected
of it
Crystal growth rate dispersion (GRD) is a phenomenon, known
as a great breadth and depth problem in the crystalline
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 2 8 3e2 9 1290product industries, where obviously identical crystals in the
same solution under identical conditions (such as tempera-
ture, supersaturation levels, and hydrodynamic) grow at
different rates. It appears to occur to different extents in all
crystallization systems [49e53]. GRD was first seen by White
andWright (1971) in sucrose batch crystallization [54]. Growth
rate dispersion broadens the crystal size distribution (CSD)
and hence affects the product quality (bulk properties) of in-
dustrial crystallizers such as filtration, drying rates, compac-
tion, content uniformity and so on. From the bioavailability
perspective, small particles have faster dissolution rate and
lower mechanical properties than the larger particles in gen-
eral [1]. Various studies try to explanation this correlation,
Judge R. A., et al. grew tetragonal lysozyme crystal and
investigate growth rate dispersion of the (110) and (101) crystal
faces as a function of sodium chloride concentration, tem-
perature, and solution pH. They reported that the lysozyme
face growth rate was independent of the solution conditions
for (110) face in compared with (101) face which was observed
to vary systematically with temperature and pH [55]. However,
there is some poor in understanding physicochemical mech-
anism of why it occurs and what contributes to it. According
to the literatures, two differentmechanisms can illustrate this
phenomenon. Firstly, random fluctuations mechanism shows
that all crystals have the same-averaged growth rate but that
individual crystals growth rates fluctuate during growth pe-
riods [56]. Secondly, constant crystal growth mechanism assumes
that crystals are born with an inherent constant growth rate
but the rate from crystal to crystal varies [57]. Moreover, the
differences in growth rates between same crystals have been
attributed to differences in molecular arrangement in crystal
unit as well as differences in internal crystal structure like
internal strains, in size and in lattice spread angle [25] and [58]
which cause difference in surface structure of crystal faces.
All in all, growth rate dispersion can be a result of different
crystal perfection [59] and [60].4. Conclusion
This article covers, in brief, the importance of crystal engi-
neering, mechanism of crystallization, methods of prepara-
tion of crystals, application of crystallization to modify
physicochemical properties of pharmaceutical materials, and
phenomenon GRD. At last, there are more works required in
crystal engineering field in order to development and design
solid particles in the desired form.r e f e r e n c e s
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